Guidelines revised for rad therapy after prostatectomy

The American Society for Radiation Oncology and the American Urological Association...Read more on AuntMinnie.comRelated Reading: ASTRO: Prior authorization delays radiation treatment ASTRO hails new anti-self-referral legislation ASTRO updates radiation oncology safety guide Societies release guideline for localized prostate cancer Societies eye role for prostate MRI-guided biopsy ASTRO, AUA issue prostate radiation therapy guideline
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Prostate cancer is the most prevalent cancer among men, with an estimated 175,000 new diagnoses in the United States in 2019. A variety of treatment options are available, including active surveillance, radiation therapy, or radical prostatectomy. The choice of treatment modality is based on a number of considerations: risk group, age, comorbidities, and performance status. Shared decision making and informed consent plays a pivotal role in the type of treatment a patient pursues. Patients must understand not only the cancer-related outcomes for their particular situation, but also the anticipated side effects of treatment.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
Postoperative biochemical recurrence of pathologically localized high-grade prostate cancer in adjuvant treatment-naïve patients. J Cancer Res Clin Oncol. 2019 Oct 14;: Authors: Heo JE, Park JS, Lee JS, Kim J, Jang WS, Cho NH, Rha KH, Choi YD, Hong SJ, Ham WS Abstract PURPOSE: To evaluate biochemical recurrence (BCR) risk in men with localized prostate cancer (PC) of pathological Gleason score (pGS) 8-10. Although such patients have low BCR-free survival (BCRFS) following radical prostatectomy (RP), they are not recommended for adjuvant radiation therapy (ART) as per current guidelines. METH...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
AbstractPurposeTo evaluate biochemical recurrence (BCR) risk in men with localized prostate cancer (PC) of pathological Gleason score (pGS) 8 –10. Although such patients have low BCR-free survival (BCRFS) following radical prostatectomy (RP), they are not recommended for adjuvant radiation therapy (ART) as per current guidelines.MethodsAmong an adjuvant treatment-na ïve cohort between 1995 and 2015, 1272 men were identified and categorized into group 1 [pGS7 (3 + 4) and pT3;n  =  654], group 2 [pGS7 (4 + 3) and pT3;n  =  408], and group 3 (pGS 8–10 an...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Laser-excited gold nanoparticles safely destroyed prostate tumors in a recent pilot study involving 16 patients with low- to intermediate-risk prostate cancer. The highly targeted approach is being developed as an alternative to prostatectomy and radiation therapy, treatments associated with adverse urinary and sexual effects.
Source: JAMA - Category: General Medicine Source Type: research
Adjuvant radiation therapy (ART) is recommended without consideration of radical prostatectomy Gleason score (RP GS) for cases with adverse features. We compared the outcomes of pathologically localized high-grade (GS 8–10) prostate cancer (PC) with those of pT3 GS 7 PC. A total of 1585 men who underwent RP between 1995 and 2015 comprised the cohort, which was divided into group 1 (RP GS 7(3 + 4) and pT3; n = 760), group 2 (RP GS 7(4 + 3) and pT3; n = 565), and group 3 (RP GS 8–10 and pT2; n = 260). Biochemical recurrence (BCR), all-cause mortality (ACM), and PC-specific mortality (PCSM) ri...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Purpose of review During the last 15 years several updates in the Gleason grading have been made. With the help of pertinent research results pathologists have gained a better insight into the meanings of several prostate cancer (PCa) patterns and know better how to classify them in the Gleason grade system. Recent findings During the last years PCa with cribriform architecture has be given much attention. Many data have also been published about the meaning of comedonecrosis and its relationship with Gleason pattern 4 and 5. The correlationship between comedonecrosis and intraductal PCa has also been highlighted in t...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: CALCULATING PROSTATE CANCER RISK, AVOIDANCE OF OVERTREATMENT IN LOCALIZED PROSTATE CANCER: Edited by Matthew R. Cooperberg and Declan G. Murphy Source Type: research
Purpose of review The clinical course of localized prostate cancer varies widely, ranging from indolent disease unlikely to require treatment to aggressive cancers meriting intensive, multimodal therapy. Management recommendations have traditionally been determined based on clinical and pathologic factors, including serum prostate - specific antigen (PSA), clinical stage, and Gleason score. Unfortunately, these factors have limited ability to describe the underlying biology of a given tumor. Tissue-based genomic tests have emerged as a promising tool to more accurately characterize prostate cancer biology and projected c...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: CALCULATING PROSTATE CANCER RISK, AVOIDANCE OF OVERTREATMENT IN LOCALIZED PROSTATE CANCER: Edited by Matthew R. Cooperberg and Declan G. Murphy Source Type: research
Salvage radiation therapy (SRT) is recommended for men with biochemically recurrent prostate cancer post-radical prostatectomy. RTOG 9601 was a randomized phase 3 clinical trial that demonstrated an overall survival (OS) benefit from the addition of long-term anti-androgen therapy to SRT. However, hormone therapy has well documented side effects and has been shown to increase cardiac event rates, and there remains no evidence of an OS benefit from hormone therapy for men treated with early SRT. Herein, we aim to determine if pre-SRT PSA can serve as both a prognostic and predictive biomarker of benefit or harm from hormone therapy.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Authors: Morgentaler A, Caliber M Abstract Introduction: The use of testosterone therapy (TTh) in men with prostate cancer (PCa) is relatively new, and controversial, due to the longstanding maxim that TTh is contraindicated in men with PCa. Scientific advances have prompted a reevaluation of the potential role for TTh in men with PCa, particularly as TTh has been shown to provide important symptomatic and general health benefits to men with testosterone deficiency (TD), including many men with PCa who may expect to live 30-50 years after diagnosis. Areas covered: This review outlines the historical underpinnings o...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
CONCLUSIONS: Prostate cancer patients experience significant declines in HRQoL after primary therapy. Additional secondary therapy after RP, in the form of EBRT and/or ADT, appears to be responsible for further deterioration in HRQoL outcomes. PMID: 31469635 [PubMed - in process]
Source: Canadian Journal of Urology - Category: Urology & Nephrology Tags: Can J Urol Source Type: research
More News: Cancer | Cancer & Oncology | Prostate Cancer | Prostatectomy | Radiation Therapy | Radiology | Urology & Nephrology